- Home
- FSBC vs SLS Comparison
FSBC vs SLS Comparison
Compare FSBC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | SLS |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 924.5M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FSBC | SLS |
|---|---|---|
| Price | $47.61 | $12.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $41.90 | $10.00 |
| AVG Volume (30 Days) | 126.8K | ★ 7.9M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 28.32 | ★ 50.00 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.25 | N/A |
| Revenue Next Year | $12.30 | $110.98 |
| P/E Ratio | $54.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.34 | $1.39 |
| 52 Week High | $48.24 | $11.06 |
Technical Indicators
Market Signals| Indicator | FSBC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 77.82 | 77.80 |
| Support Level | $40.35 | $3.72 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.30 | 0.80 |
| MACD | 0.32 | 0.29 |
| Stochastic Oscillator | 86.55 | 96.23 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.